Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model

International Journal of Cancer

Volumn 132, Issue 4, 2012, Pages 843-853

  Chirasani, Sridhar R ^a   Leukel, Petra ^a   Gottfried, Eva ^a   Hochrein, Jochen ^a   Stadler, Katrin ^a   Neumann, Bernhard ^a   Oefner, Peter J ^a   Gronwald, Wolfram ^a   Bogdahn, Ulrich ^a   Hau, Peter ^a   Kreutz, Marina ^a   Grauer, Oliver M ^a,b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

dendritic cell; diclofenac; glioma; lactate; LDH A; regulatory T cell; Stat3; TLR

Indexed keywords

DICLOFENAC; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 5; LACTIC ACID; RESIQUIMOD; STAT3 PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; EX VIVO STUDY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GLIOMA; GLIOMA CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE MARROW CELLS; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; DICLOFENAC; DISEASE MODELS, ANIMAL; FEMALE; GLIOMA; IMIDAZOLES; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ISOENZYMES; L-LACTATE DEHYDROGENASE; LACTIC ACID; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84871375453     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27712     Document Type: Article

References (47)

1. Harris AL,. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47. (Pubitemid 37328806)
2. Gordan JD, Simon MC,. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007; 17: 71-7. (Pubitemid 46109295)
3. Gordan JD, Thompson CB, Simon MC,. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007; 12: 108-13. (Pubitemid 47199124)
4. Walenta S, Mueller-Klieser WF,. Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 2004; 14: 267-74. (Pubitemid 38903231)
5. Semenza GL, Jiang BH, Leung SW, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996; 271: 32529-37.
6. Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997; 94: 6658-63. (Pubitemid 27281920)
7. Walenta S, Wetterling M, Lehrke M, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000; 60: 916-21. (Pubitemid 30129526)
8. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003; 89: 877-85. (Pubitemid 37175811)
9. Li X, Jin H, Lu Y, et al. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004; 17: 10-20. (Pubitemid 38332096)
10. Yamasaki F, Kurisu K, Kajiwara Y, et al. Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma. Neuro Oncol 2011; 13: 791-801.
11. Pashenkov M, Teleshova N, Link H,. Inflammation in the central nervous system: the role for dendritic cells. Brain Pathol 2003; 13: 23-33. (Pubitemid 36133789)
12. Karman J, Ling C, Sandor M, et al. Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol 2004; 173: 2353-61. (Pubitemid 39063091)
13. Mellman I, Steinman RM,. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106: 255-8. (Pubitemid 32772607)
14. Napolitani G, Rinaldi A, Bertoni F, et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6: 769-76. (Pubitemid 43090462)
15. Wei J, Duramad O, Perng OA, et al. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2007; 104: 18169-74. (Pubitemid 350210839)
16. Iwasaki A, Medzhitov R,. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-95. (Pubitemid 41057715)
17. Kawai T, Akira S,. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-84.
18. Grauer O, Poschl P, Lohmeier A, et al. Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-β2. J Neurooncol 2007; 82: 151-61. (Pubitemid 46431857)
19. Pinzon-Charry A, Maxwell T, Lopez JA,. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005; 83: 451-61. (Pubitemid 41805745)
20. Gottfried E, Kreutz M, Mackensen A,. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 2008; 19: 65-77. (Pubitemid 351200062)
21. Grauer OM, Wesseling P, Adema GJ,. Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol 2009; 19: 674-93.
22. Gottfried E, Kunz-Schughart LA, Ebner S, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 2006; 107: 2013-21. (Pubitemid 43289385)
23. Singer K, Gottfried E, Kreutz M, et al. Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother 2010; 60: 425-31.
24. Williams CS, Watson AJ, Sheng H, et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000; 60: 6045-51.
25. Johnsen JI, Lindskog M, Ponthan F, et al. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 2004; 64: 7210-15. (Pubitemid 39372053)
26. Tegeder I, Pfeilschifter J, Geisslinger G,. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-72. (Pubitemid 32927924)
27. Takada Y, Bhardwaj A, Potdar P, et al. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-ÎB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004; 23: 9247-58. (Pubitemid 40069695)
28. Gronwald W, Klein MS, Kaspar H, et al. Urinary metabolite quantification employing 2D NMR spectroscopy. Anal Chem 2008; 80: 9288-97.
29. Grauer OM, Nierkens S, Bennink E, et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121: 95-105. (Pubitemid 46753856)
30. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109-20.
31. Inoue A, Muranaka S, Fujita H, et al. Molecular mechanism of diclofenac-induced apoptosis of promyelocytic leukemia: dependency on reactive oxygen species, Akt, Bid, cytochrome and caspase pathway. Free Radic Biol Med 2004; 37: 1290-9. (Pubitemid 39302541)
32. Fantin VR, St. Pierre J, Leder P,. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9: 425-34. (Pubitemid 43832190)
33. Yamanaka R, Zullo SA, Tanaka R, et al. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Neurosurg Focus 2000; 9: e7.
34. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004; 27: 452-9. (Pubitemid 39447353)
35. Hussain SF, Yang D, Suki D, et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006; 8: 261-79. (Pubitemid 46542651)
36. Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009; 15: 114-23.
37. Saraiva M, O'Garra A,. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10: 170-81.
38. Cheng F, Wang HW, Cuenca A, et al. A critical role for Stat3 signaling in immune tolerance. Immunity 2003; 19: 425-36. (Pubitemid 37153418)
39. Hussain SF, Kong LY, Jordan J, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007; 67: 9630-6. (Pubitemid 47621208)
40. Kortylewski M, Kujawski M, Herrmann A, et al. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res 2009; 69: 2497-505.
41. Dovedi SJ, Kirby JA, Atkins H, et al. Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer. J Urol 2005; 174: 332-7; discussion 37. (Pubitemid 40825752)
42. Zelenay S, Lopes-Carvalho T, Caramalho I, et al. Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci USA 2005; 102: 4091-6. (Pubitemid 40388560)
43. Sutmuller RP, den Brok MH, Kramer M, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006; 116: 485-94. (Pubitemid 43228366)
44. Bergmann C, Strauss L, Zeidler R, et al. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007; 67: 8865-73. (Pubitemid 47437463)
45. Fujita M, Kohanbash G, Fellows-Mayle W, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011; 71: 2664-74.
46. Grauer OM, Molling JW, Bennink E, et al. TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 2008; 181: 6720-9.
47. Villalonga N, David M, Bielanska J, et al. Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels. Biochem Pharmacol 2010; 80: 858-66.